Oncolytic viruses are a novel and effective way to treat cancers by infecting and destroying cancer cells, but clinical delivery necessitates creative strategies to account for the required safety protocols, deep-freeze storage, and rigorous clinical oversight. The University of North Carolina (UNC) Lineberger Comprehensive Cancer Center is a referral center for the only currently FDA-approved oncolytic virus therapy for cancer, talimogene laherparepvec, and its staff noticed that a common pain point for patients receiving this treatment is the extensive time spent in appointments.
In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Morgan Gwynn, PharmD, BCOP, CPP, an Oncology Clinical Pharmacist Practitioner at UNC Lineberger, about her program’s development of a pharmacist-led care model to make oncolytic virus treatments more efficient for patients and providers. By moving toxicity assessment, clinical review, and dose planning to pre-treatment telemedicine visits, the program reduced treatment time by more than 2 hours per session and helped decrease unnecessary clinic visits and drug waste.
“Just because there’s one way that things are done, [that] doesn’t mean that’s the only way things can be done...Finding creative solutions that benefit...the patient, the physician, and our pharmacy...was key.” – Morgan Gwynn, PharmD, BCOP, CPP
Guest:
Morgan Gwynn, PharmD, BCOP, CPP
Oncology Clinical Pharmacist Practitioner
University of North Carolina Medical Center, UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
October 28, 2026
September 10, 2026
